Downstream Processing Industry News

  1. Omeros Announces Toxicology Data That Support Advancing MASP-2 Inhibitor Into Clinical Trials 3/28/2013
  2. Biologics Research Promises To Bolster Future Of Medicine 3/11/2013

    America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

  3. IGF-1 And Long IGF-1 LR3 Is There A Difference? US Peptides Discusses 2/11/2013

    Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects.

  4. Amgen Outlines Long-Term Strategy 2/7/2013

    Amgen (NASDAQ: AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors inNew York City.

  5. Generex Provides An Overview Of Its Cancer Immunotherapy Product, AE37, And Potential In Early Breast Cancer Given Current And Potential Future Therapies 1/30/2013

    Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

  6. DSM Announces License Agreement With Amgen For Use Of DSM's XD® Cell Culture Patents 1/15/2013

    DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a non-exclusive license agreement with Amgen Inc. for access to DSM's proprietary XD® high cell density process patents.

  7. BioInvent Recruits New Chief Executive Officer 1/9/2013

    BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.

  8. Star Scientific, Inc./Rock Creek Pharmaceuticals Report Positive Initial Results Of ASAP Human Thyroid Health Study Showing Benefits In Immune System Support 1/7/2013

    Glen Allen, VA /PRNewswire/ - Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health.

  9. Gradalis, Inc. Closes $24M In Series B Financing To Advance Late-Stage Trials Of FANG™ Personalized Cancer Vaccine 1/3/2013

    Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG™, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG.

  10. ArmaGen Technologies, Inc. Hires Biotech Executive As CEO 1/3/2013

    ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway , Ph.D. as Chief Executive Office and member of the Board of Directors.